Investing.com -- Moderna (NASDAQ: MRNA) shares dropped 13% pre-open on Monday as investors reacted to the weekend news that the U.S. Food and Drug Administration’s (FDA) top vaccine official, Dr.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback